Furthermore, MTCH2 depletion induces ferroptosis to suppress CRC liver metastasis via the E2F4/TFRC axis and sensitizes tumors to sorafenib treatment, supporting MTCH2 as a novel target to improve antitumor therapy. The gene discussed is MTCH2; the disease is colorectal carcinoma.